Mit's Linctus Codeinae offers reprieve by thwarting the rising ache passageways by holding to opiate receptors originated in the CNS. It also aid stifle cough by straight targeting in the medulla.

Excretion: Mit's Linctus Codeinae is normally discharge through the urine, mostly as conjugates along with glucuronic acid.

Mit's Linctus Codeinae Side Effects

Addiction, withdrawal symptoms; vomiting, nausea, diarrhea , constipation; confusion, drowsiness,; intricacy in micturition, urinary retention ,biliary or ureteric spasms; dizziness, dry mouth, sweating, headache, facial flushing, vertigo, tachycardia, bradycardia, palpitations, hypothermia, orthostatic hypotension, restlessness, decreased libido , mood changes, miosis, hallucination,; increased intracranial pressure, muscle hardening.

Potentially Fatal: hypotension and respiratory depression, along with circulatory malfunction and intense coma (occurrence with larger dosage). Spasm, tremor (particularly in kids and infants). Rhabdomyolysis. COnsutl a doctor immediately in case any symptoms occur or become persistent.

These may not be the complete list of possible adverse reactions of Mit's Linctus Codeinae Co, for detailer information consult your nereast health care service provider.

Special Precautions

adrenocortical deficiency, Hypothyroidism, Injured hepatic or impaired renal function, hypotension, prostatic hyperplasia, shock, myasthenia gravis, awkward or inflammatory bowel disorders.

Neonates Infants, decrease dosage in aged or incapacitated subjects. May weaken aptitude to drive or manage heavy machinery. Pregnancy and Lactation.

Other Drug Interactions

Improved depressant results with alcohol, anxiolytics, anesthetics, hypnotics, antipsychotics and TCAs. potential CNS depression actions with MAOIs.

may well modify actions of supplementary composites e.g. mexiletine, cyclizine, cisapride, domperidone and metoclopramide.

Codeine and Pregnancy

Contraindicated in pregnancy.

Category C: Medical studies in animals have exposed unfavorable reactions on the fetus (embryocidal or teratogenico or other) and there are no restricted clinical trials in pregnant women or clinical research in animals and women are not accessible. Mit's Linctus Codeinae Co should be used only if the possible benefits outweigh the possible danger to the fetus.

If protracted use/high doses at term:

Category D: There is optimistic confirmation of human fetal danger, but the possible benefits from administration of Mit's Linctus Codeinae Co during pregnancy may be satisfactory in spite of the danger (e.g., if the drug is required in a life-threatening circumstances or for a severe ailment for which safer medications cannot be administered or are unproductive).